OSTX Quote, Financials, Valuation and Earnings

Actinium Pharmaceuticals has a net margin of -- compared to OS Therapies's net margin of -11511.11%. OS Therapies's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.

OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 703.57%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 214.47%. Given that OS Therapies has higher upside potential than Actinium Pharmaceuticals, analysts believe OS Therapies is more attractive than Actinium Pharmaceuticals.

OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.

OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

OS Therapies quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. OS Therapies's net income of -$3.9M is higher than Actinium Pharmaceuticals's net income of -$15.9M. Notably, OS Therapies's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Citius Oncology has a net margin of -- compared to OS Therapies's net margin of --. OS Therapies's return on equity of -- beat Citius Oncology's return on equity of --.

OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 703.57%. On the other hand Citius Oncology has an analysts' consensus of $3.00 which suggests that it could grow by 91.08%. Given that OS Therapies has higher upside potential than Citius Oncology, analysts believe OS Therapies is more attractive than Citius Oncology.

OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Citius Oncology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. Citius Oncology pays out -- of its earnings as a dividend.

OS Therapies quarterly revenues are --, which are smaller than Citius Oncology quarterly revenues of --. OS Therapies's net income of -$3.9M is higher than Citius Oncology's net income of -$7.7M. Notably, OS Therapies's price-to-earnings ratio is -- while Citius Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus -- for Citius Oncology. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of -- compared to OS Therapies's net margin of --. OS Therapies's return on equity of -- beat CEL-SCI's return on equity of --.

OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 703.57%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 6699.55%. Given that CEL-SCI has higher upside potential than OS Therapies, analysts believe CEL-SCI is more attractive than OS Therapies.

OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.097%.

OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

OS Therapies quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. OS Therapies's net income of -$3.9M is higher than CEL-SCI's net income of -$6.6M. Notably, OS Therapies's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to OS Therapies's net margin of -711.67%. OS Therapies's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 703.57%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1059.83%. Given that IGC Pharma has higher upside potential than OS Therapies, analysts believe IGC Pharma is more attractive than OS Therapies.

OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.452, suggesting its more volatile than the S&P 500 by 45.212%.

OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

OS Therapies quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. OS Therapies's net income of -$3.9M is lower than IGC Pharma's net income of -$1.8M. Notably, OS Therapies's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus 20.11x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.